IL130656A0 - Soluble CTLA4 mutant molecules - Google Patents

Soluble CTLA4 mutant molecules

Info

Publication number
IL130656A0
IL130656A0 IL13065698A IL13065698A IL130656A0 IL 130656 A0 IL130656 A0 IL 130656A0 IL 13065698 A IL13065698 A IL 13065698A IL 13065698 A IL13065698 A IL 13065698A IL 130656 A0 IL130656 A0 IL 130656A0
Authority
IL
Israel
Prior art keywords
mutant molecules
soluble ctla4
ctla4 mutant
soluble
molecules
Prior art date
Application number
IL13065698A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL130656A0 publication Critical patent/IL130656A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13065698A 1997-01-31 1998-01-29 Soluble CTLA4 mutant molecules IL130656A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3659497P 1997-01-31 1997-01-31
PCT/US1998/001880 WO1998033513A1 (en) 1997-01-31 1998-01-29 Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number Publication Date
IL130656A0 true IL130656A0 (en) 2000-06-01

Family

ID=21889481

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13065698A IL130656A0 (en) 1997-01-31 1998-01-29 Soluble CTLA4 mutant molecules

Country Status (17)

Country Link
US (2) US20030035816A1 (es)
EP (2) EP1557173A1 (es)
JP (1) JP2001510473A (es)
KR (1) KR20000070633A (es)
CN (1) CN1244803A (es)
AR (1) AR007225A1 (es)
AU (1) AU725016B2 (es)
BR (1) BR9806764A (es)
CA (1) CA2278771A1 (es)
HU (1) HUP0001971A3 (es)
IL (1) IL130656A0 (es)
NO (1) NO993708L (es)
NZ (1) NZ336009A (es)
PL (1) PL334898A1 (es)
RU (2) RU2235555C2 (es)
WO (1) WO1998033513A1 (es)
ZA (1) ZA98533B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU2926401A (en) * 2000-01-03 2001-07-16 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
IL152315A (en) * 2000-05-26 2010-04-15 Bristol Myers Squibb Co Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN1438894A (zh) * 2000-06-09 2003-08-27 布里斯托尔-迈尔斯斯奎布公司 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SK287940B6 (sk) * 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
JP4837880B2 (ja) * 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
RU2353384C2 (ru) * 2003-08-04 2009-04-27 Бристол-Маерс Сквибб Компани Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
KR101391457B1 (ko) 2005-12-20 2014-05-19 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2009058564A2 (en) * 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
CA2580812A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN1438894A (zh) * 2000-06-09 2003-08-27 布里斯托尔-迈尔斯斯奎布公司 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法
SK287940B6 (sk) * 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
JP4837880B2 (ja) * 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
RU2353384C2 (ru) * 2003-08-04 2009-04-27 Бристол-Маерс Сквибб Компани Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4

Also Published As

Publication number Publication date
ZA98533B (en) 1999-07-22
NO993708L (no) 1999-09-28
AU725016B2 (en) 2000-10-05
NO993708D0 (no) 1999-07-30
KR20000070633A (ko) 2000-11-25
RU2004115039A (ru) 2005-10-27
NZ336009A (en) 2001-06-29
US20030035816A1 (en) 2003-02-20
HUP0001971A3 (en) 2002-01-28
EP1557173A1 (en) 2005-07-27
WO1998033513A1 (en) 1998-08-06
PL334898A1 (en) 2000-03-27
EP0988047A1 (en) 2000-03-29
HUP0001971A2 (hu) 2000-10-28
AR007225A1 (es) 1999-10-27
RU2235555C2 (ru) 2004-09-10
US20040014171A1 (en) 2004-01-22
AU6052598A (en) 1998-08-25
CA2278771A1 (en) 1998-08-06
CN1244803A (zh) 2000-02-16
BR9806764A (pt) 2000-03-14
EP0988047A4 (en) 2003-05-14
JP2001510473A (ja) 2001-07-31

Similar Documents

Publication Publication Date Title
IL130656A0 (en) Soluble CTLA4 mutant molecules
AU1709299A (en) Mixer-injectors
AU8921698A (en) Follistatin-3
AU9414098A (en) Ascorbyl-phosphoryl-cholesterol
AU6598798A (en) Resorcinyl-triazines
AU1027499A (en) 32P-polyphosphazene
AU9513298A (en) Fluoranthenopyrans
AU5272198A (en) EMP-charge-eliminator
AU4117497A (en) Micropolarimeter
AU6998698A (en) Dioxacycloalkan-8-one
AU6185898A (en) Clavaspirins
AU6525998A (en) Improved metallo-endopeptidases
AU7761998A (en) Korrosionsschutzanstrichstoff
AU8214598A (en) 3-benzylpiperidine
AU4469997A (en) Heregulin-gamma
AU8991998A (en) Renovative pipeliner
AU5391798A (en) Thiamacrolides
AU9183798A (en) Catamaran - bicycle - kayak
AU5540298A (en) Rockbolts
AU6060598A (en) Multi-hopper
AU6237398A (en) N-het-substituted glycerophosphoethanolamines
AU6507298A (en) Renovative pipeliner
AU7780498A (en) Cafetiere
AU8121298A (en) G-seat
AU749312C (en) Novel modified tie-2 receptor ligands